Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study
Piero Ruggenenti, Monica Cortinovis, Aneliya Parvanova, Matias Trillini, Ilian Iliev, Antonio Bossi, Antonio Belviso, M Aparicio, Roberto Trevisan, Stefano Rota, Annalisa Perna, Tobia Peracchi, Nadia Rubis, Davide Martinetti, Silvia Prandini, Flavio Gaspari, Fabiola Carrara, Salvatore De Cosmo, Giancarlo Tonolo, Ruggero Mangili, Giuseppe Remuzzi (2021). Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. , 18(7), DOI: https://doi.org/10.1371/journal.pmed.1003691.
Article41 days agoPodocyte Number in Normotensive Type 1 Diabetic Patients With Albuminuria
Kathryn White, Rudolf W. Bilous, Sally M. Marshall, Meguid El Nahas, Giuseppe Remuzzi, Giampiero Piras, Salvatore De Cosmo, Giancarlo Viberti (2002). Podocyte Number in Normotensive Type 1 Diabetic Patients With Albuminuria. , 51(10), DOI: https://doi.org/10.2337/diabetes.51.10.3083.
Article41 days agoPPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies
Salvatore De Cosmo, Sabrina Prudente, Olga Lamacchia, Emanuela Lapice, Eleonora Morini, Rosa Di Paola, Massimiliano Copetti, Piero Ruggenenti, Giuseppe Remuzzi, Olga Vaccaro, Mauro Cignarelli, Vincenzo Trischitta (2011). PPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. , 26(12), DOI: https://doi.org/10.1093/ndt/gfr187.
Article41 days agoImpact of the <i>PPAR</i>-γ<i>2</i> Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT
Salvatore De Cosmo, Nicola Motterlini, Sabrina Prudente, Fabio Pellegrini, Roberto Trevisan, Antonio Bossi, Giuseppe Remuzzi, Vincenzo Trischitta, Piero Ruggenenti (2009). Impact of the <i>PPAR</i>-γ<i>2</i> Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. , 58(12), DOI: https://doi.org/10.2337/db09-0407.
Article41 days agoImpact of the <i>PPAR</i>-γ<i>2</i> Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT
Salvatore De Cosmo, Nicola Motterlini, Sabrina Prudente, Fabio Pellegrini, Roberto Trevisan, Antonio Bossi, Giuseppe Remuzzi, Vincenzo Trischitta, Piero Ruggenenti (2009). Impact of the <i>PPAR</i>-γ<i>2</i> Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. , 58(12), DOI: https://doi.org/10.2337/db09-0407.
Article41 days ago